A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARα and T18 oncoproteins

Nature Genetics

Volumn 23, Issue 3, 1999, Pages 287-295

  Zhong, Sue ^a   Delva, Laurent ^a   Rachez, Christophe ^a   Cenciarelli, Cristina ^a   Gandini, Domenica ^a   Zhang, Hui ^a   Kalantry, Sundeep ^a   Freedman, Leonard P ^a   Pandolfi, Pier Paolo ^a  

^a Department of Population Medicine and Diagnostic Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; RETINOIC ACID; RETINOID X RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CANCER MODEL; CARCINOGENESIS; CELL GROWTH; GENE INDUCTION; GROWTH INHIBITION; LEUKEMOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; TUMOR GROWTH;

ANIMALS; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; CREB-BINDING PROTEIN; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEIN ISOFORMS; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSFECTION; TRETINOIN;

ANIMALIA;

EID: 0032721510     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/15463     Document Type: Article

References (48)

1. Smith, M.A., Parkinson, D.R., Cheson, B.D. & Friedman, M.A. Retinoids in cancer therapy J. Clin. Oncol. 10, 839-864 (1992).
2. Gudas, L.J., Sporn, M.B. & Roberts, A.B. The Retinoids: Cellular Biology and Biochemistry of the Retinoids 443-520 (Raven Press, New York, 1994).
3. Chambon, P. A decade of molecular biology of retinoic acid receptors. FASEB J. 10, 955-960 (1996).
4. He, L-Z., Merghoub, T. & Pandolfi, P.P. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogens 18, 5278-5292 (1999).
5. Borden, K.L.B. et al. The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML. EMBO J. 14, 1532-1541 (1995).
6. Perez, A. et al. PML/RAR homodimers: distinct DNA binding properties and heteromeric interactions with RAR. EMBO J. 12, 3171-3182 (1993).
7. Fagioli, M. et al. Identification of various PML gene isoforms and characterization of their origin and expression pattern. Oncogene 7, 1083-1091 (1992).
8. Hodges, M., Tissot, C., Howe, K., Grimwade, D. & Freemont, P.S. Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies. Am. J. Hum. Genet. 63, 297-304 (1998).
9. Gaboli, M., Gandini, D., Delva, L., Wang, Z.G. & Pandolfi, P.P. Acute promyelocytic leukemia as a model for cross-talk between interferon and retinoic acid pathways: from molecular biology to clinical applications. Leuk. Lymphoma 30, 11-22 (1998).
10. Mu, Z.M., Chin, K.V., Liu, J.H., Lozano, G. & Chang, K.S. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol. Cell. Biol. 14, 6858-6867 (1994).
11. Wang, Z.G. et al. Role of PML in cell growth and the retinoic acid pathway Science 279, 1547-1551 (1998).
12. Wang, Z.-G. et al. Pml is essential for multiple apoptotic pathways. Nature Genet. 20, 266-271 (1998).
13. Miki, T. et al. Development of a highly efficient expression cDNA cloning system: application to oncogene isolation. Proc. Natl Acad. Sci. USA 88, 5167-5171 (1991).
14. Le Douarin, B. et al. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J. 14, 2020-2033 (1995).
15. Klugbauer, S. & Rabes, H.M. The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. Oncogene 18, 4388-4393 (1999).
16. vom Baur, E. et al. Differential ligand dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J. 15, 110-124 (1995).
17. de Thé, H., Vivanco-Ruiz, M.d.M., Tiollais, P., Stunnenberg, H. & Dejean, A. Identification of a retinoic acid responsive element in the retinoic acid receptor β gene. Nature 343, 177-180 (1990).
18. Rachez, C. et al. A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes Dev. 12, 1787-1800 (1998).
19. Rachez, C et al. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 398, 824-828 (1999).
20. Näär, A.M. et al. Composite co-activator ARC mediates chromatin-directed transcriptional activation. Nature 398, 828-832 (1999).
21. Fondell, J.D., Ge, H. & Roeder, R.G. Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. Proc. Natl Acad. Sci. USA 93, 8329-8333 (1996).
22. Chakravati, D. et al. Role of CBP/P300 in nuclear receptor signalling. Nature 383, 99-103 (1996).
23. Bannister, A.J. & Kouzarides, T. The CBP co-activator is a histone acetyltransferase. Nature 384, 641-643 (1996).
24. LaMorte, V.J., Dyck, J.A., Ochs, R.L. & Evans, R.M. Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proc. Natl Acad. Sci. USA 95, 4991-4996 (1998)
25. Fagioli, M. et al. Cooperation between the RING + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival. Oncogene 16, 2905-2913 (1998).
26. Vallian, S. et al. Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein. Oncogene 16, 2843-2853 (1998).
27. Vallian, S., Chin, K.V. & Chang, K.S. The promyelocytic leukemia protein interacts with Sp1 and inhibits its transactivation of the epidermal growth factor receptor promoter. Mol. Cell. Biol. 18, 7147-7156 (1998).
28. Alcalay, M. et al. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol. Cell. Biol. 18, 1084-1093 (1998).
29. Guiochon-Mantel, A. et al. Effect of PML and PML-RAR on the transactivation properties and subcellular distribution of steroid hormone receptors. Mol. Endocrinol. 9, 1791-1803 (1995).
30. Liu, M., Iavarone, A. & Freedman, L.P. Retinoid induction of U937 cell differentiation: transcriptional activation of the human p21WAF1/CIP1 gene by retinoic acid receptor. J. Biol. Chem. 271, 31723-31728 (1996).
31. Pomponi, F. et al. Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. Blood 88, 3147-3159 (1996).
32. Schüle, R. et al. Retinoic acid is a negative regulator of AP-1-responsive genes. Proc. Natl Acad. Sci. USA 88, 6092-6096 (1991).
33. Kamei, Y. et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85, 403-414 (1996).
34. Huang, C. et al. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc. Natl Acad. Sci. USA 94, 5826-5830 (1997).
35. Nason-Burchenal, K. et al. Interferon augments PML and PML/RARα expression in normal meyloid and acute promyelocytic cells and cooperates with all-trans retinoic acid to induce maturation of a retinoid resistant promyelocytic cell line. Blood 88, 3926-3936 (1996).
36. Flenghi, L. et al. Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia. Blood 85, 1871-1880 (1995).
37. de Thé, H., Marchio, A., Tiollais, P. & Dejean, A. Differential expression and ligand regulation of the retinoic acid receptor α and β genes. EMBO J. 8, 429-433 (1989).
38. Vasios, G.W., Gold, J.D., Petkovitch, M., Chambon, P. & Gudas, L.J. A retinoic acid-responsive element is present in the 5′ flanking region of the laminin B1 gene. Proc. Natl Acad. Sci. USA 86, 9099-9103 (1989).
39. Manshouri, T. et al. Downregulation of RARα in mice by antisense transgene leads to a compensatory increase in RARβ and RARγ and development of lymphoma. Blood 89, 2507-2515 (1997).
40. David, G., Terris, B., Marchio, A., Lavau, C. & Dejean, A. The acute promyelocytic leukemia PML-RARα protein induces hepatic preneoplastic and neoplastic lesions in transgenic mice. Oncogene 14, 1547-1554 (1997).
41. He, L.Z. et al. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nature Genet. 18, 126-135 (1998).
42. Grignani, F. et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 391, 815-818 (1998).
43. Lin, R.J. et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391, 811-814 (1998).
44. Boddy, M.N., Howe, K., Etkin, L.D., Solomon, E. & Freemont, P.S. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 13, 971-982 (1996).
45. Filvaroff, E., Stern, D.F. & Dotto, G.P. Tyrosine phosphorylation is an early and specific event involved in primary keratinocyte differentiation. Mol. Cell. Biol. 10, 1164-1173 (1990).
46. Glass, C.K., Holloway, J.M., Devary, O.V. & Rosenfeld, M.G. The thyroid hormone receptor binds with opposite transcriptional effects to a common sequence motif in thyroid hormone and estrogen response elements. Cell 54, 313-323 (1988).
47. Jin, S. & Scotto, K.W. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell. Biol. 18, 4377-4384 (1998).
48. Qin, X.Q., Chittenden, T., Livingston, D. & Kaelin, W.G. Identification of a growth suppression domain within the retinoblastoma gene product Genes Dev. 6, 953-964 (1992).